AstraZeneca secured a Federal Court injunction in Australia blocking Pharmacor from selling generic dapagliflozin while a ...

Fallopian tube cancer, a rare gynecologic cancer, is gaining awareness due to its potential origin for many high-grade serous ovarian cancers. New diagnostics improve early detection and treatment, ...

Foreign drug makers face pressure in the Chinese market, from tighter regulatory oversight to growing local competition ...

Chinese prosecutors have brought formal charges against AstraZeneca and its former executives following investigations into alleged illegal patient data collection and importation of drugs. | Chinese ...

On CNBC's “Halftime Report Final Trades,” Joshua Brown, co-founder and CEO of Ritholtz Wealth Management, said he remains ...

AZN gears up for Q4 results as cancer, diabetes and rare disease drugs drive sales expectations ahead of the Feb. 10 earnings report.

Once operational, the new Sphere set to be built in National Harbor will generate $1.5 billion in revenue and create thousands of jobs across Maryland, according to new analysis from accounting firm ...

AstraZeneca PLC (NASDAQ:AZN) is one of the stocks in focus on Jim Cramer’s game plan. Cramer mentioned the company during the ...

AstraZeneca's full-year 2025 results are due on 10 February. Learn what investors should watch including Tagrisso sales, ...

The company's shares rose 11% in the fourth quarter to close at 137.90 pounds on Dec. 31.

AstraZeneca will push the pill, elecoglipron, into a comprehensive late-stage program that will test the drug as a monotherapy, as part of a combination regimen and for several indications.

In a report released today, Matthew Weston from UBS maintained a Buy rating on AstraZeneca, with a price target of £163.00. Weston covers the Healthcare sector, focusing on stocks such as Novo Nordisk ...